Venture CapitalFresenius Ventures’ managing director: Europe has the investors. It needs the capital.Following Fresenius’ launch of a €200 million healthcare venture fund in July, we invited Thomas Thestrup, managing director of Fresenius Ventures, to share his perspective in the Autumn issue of … more ➔
clinical dataOSE reports positive Phase 2 data, but questions remainFrench biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial. However, … more ➔
RegulatoryCHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launchEach month, the European Medicines Agency’s human medicines committee (CHMP) weighs in on which drugs should reach European patients — and which should not. Here are eight decisions from its October … more ➔
fundraisingNouscom raises €120M to advance cancer prevention vaccineSwiss biotech Nouscom has raised €120 million in an oversubscribed Series D financing to advance NOUS-209, an experimental cancer vaccine designed to prevent tumors in people with Lynch syndrome, into … more ➔
clinical dataOsivax misses Phase 2b flu vaccine endpoint, shifts focus to combinationsFrench-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, which achieved a nonsignificant efficacy estimate of 24% against a predefined … more ➔
AppointmentsEvotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOsEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a swift scientific leadership change … more ➔
fundraisingMicrobiotica raises £36M to test gut-bacteria capsule in ulcerative colitisU.K. microbiome company Microbiotica has raised £36 million (€43 million), the first close of a Series C round led by the British Business Bank, to take its ulcerative colitis drug MB310 into Phase … more ➔
CAR-T cell therapyLakefront offloads CAR-T programs to Armed Cell as Mankind Pharma takes control of the Belgian startupLakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell Therapeutics for €8 million upfront, while India’s Mankind Pharma has agreed to acquire … more ➔
fundraisingOMass raises $310M in Europe’s second-largest biotech round of 2026Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule pipeline in endocrinology and immunology, including a potential treatment … more ➔
clinical dataBioNTech’s mRNA cancer vaccine misses Phase 2/3 endpointBioNTech’s BNT113, combined with Keytruda, failed to significantly improve progression-free survival in a Phase 2/3 head and neck cancer trial. The study will continue to assess whether the combination … more ➔
